This guideline followed the American College of Rheumatology (ACR) guideline development process (http://www.rheumatology.org/Practice-Quality/Clinical-Support/Clinical-Practice-Guidelines). This process includes using GRADE methodology (www.gradeworkinggroup.org) to rate the quality of the available evidence and to develop the recommendations (1-3). GRADE methodology specifies that panels
make recommendations based on the balance of benefits and harms, the quality of the evidence (i.e., confidence in effect estimates), and patients' values and preferences. In this case, however, the panel did not adhere to GRADE guidance on two issues. First, the panel made some GRADE recommendations without a formal rating of the quality of the evidence that came from non-RMD populations because the magnitude of indirect evidence that was considered was excessive. Second, the panel chose to make a number of strong recommendations based on low or very low quality evidence that could not be justified using GRADE criteria (3) because, despite the limitations of the available evidence, the potential harm of not proceeding with the recommendation was thought to outweigh other potential harms. The potential harms of not proceeding with these recommendations included potentially catastrophic negative outcomes such as an organ-or life-threatening disease flare or a potentially fatal thromboembolic event.
While unlikely, these are severe and unpredictable risks in many situations and were felt to warrant strong recommendations despite the low quality evidence. 
Framework for the Reproductive Health Guideline Development and Scope of the Guideline
At the scoping meeting, the Core Leadership Team, Voting Panel and Expert Panel decided that the guideline would address several areas, including medications and pregnancy (safety of paternal medication exposure, medication safety during pregnancy, and medication safety during lactation); management of pregnancy (counseling and medication transition in anticipation of pregnancy, pregnancy management issues, and management of anti-Ro/SSA and/or anti-La/SSB antibody as well as antiphospholipid antibody positive patients); fertility (including assisted reproductive technology in RMD patients, and fertility preservation with cyclophosphamide therapy); and other reproductive health issues (contraception in RMD patients, menopause/hormone replacement therapy). Human papillomavirus (HPV) prevention and screening and treatment of gynecologic cancers in RMD patients were initially considered as part of this project, but were removed during the scoping meeting due to the already broad spectrum of topics covered as well as the consideration that these topics might be better grouped with potential future recommendations concerning vaccination and malignancy in RMD patients.
Recommendations regarding long-term outcomes of offspring were originally considered as well, but ultimately were felt to be beyond the scope of the current guideline. 
Systematic Synthesis of the Literature

Moving from Evidence to Recommendations
Given that GRADE methodology specifies that panels make recommendations based on the balance of benefits and harms, the quality of the evidence, and patients' values and preferences, deciding on the balance between desirable and undesirable outcomes The Voting Panel made every effort to adhere to GRADE guidance that specifies that strong recommendations should in general be based on high or moderate quality evidence, and that there are a restricted set of circumstances that warrant strong recommendations based on low or very low quality evidence (3) . Much of the evidence from non-RMD populations was likely of moderate quality; however, this evidence was not formally graded due to inadequate time and resources. Given the low and very quality evidence specific to RMD populations, the data from non-RMD populations ultimately played an important role in the decision-making process. Furthermore, it should be noted that many of the strong recommendations with low or very low quality evidence relied on the possibility of potentially catastrophic negative outcomes such as an organ-or life-threatening disease flare or a potentially fatal thromboembolic event, unlikely but real risks that were felt to warrant strong recommendations despite the low quality evidence.
Consensus Building
During a two-day face-to-face meeting and subsequent webinars and group emails, Voting Panel members voted on the direction (for or against) and strength (conditional or strong) of the recommendations related to the PICO questions. Not all PICOgenerated recommendations were voted upon, although all were presented to the Voting Panel; as a result, numbering of guideline statements is not sequential. Some recommendation statements were dropped due to lack of data or relevance, and others were combined or changed to good practice statements based on level of evidence and Voting Panel discussion. A 'good practice' statement is one in which a large and compelling body of indirect evidence, made up of linked evidence using several indirect comparisons, strongly supports the net benefit of the recommended action. In many situations the case for a good practice statement rather than a GRADE recommendation is the use of time in collecting and summarizing the relevant evidence.
Recommendations required a 70% level of agreement as used previously in other similar processes (6) . If 70% agreement was not achieved during an initial vote, the panel members held additional discussions before re-voting. For all conditional recommendations, a written explanation is provided, describing the reasons for this decision.
Moving from Recommendations to Practice
These recommendations are designed to help health care providers, caregivers, and patients engage in shared decision-making regarding disease management. Level of disease activity, comorbidities, response and tolerance of prior therapies, and patientspecific factors, values and preferences at the given point in their reproductive lifespan, should all be taken into consideration in choosing optimal therapy.
